Home › Uterine Cancer › California › Baldwin Park
Uterine Cancer clinical trials in Baldwin Park, CA
3 studies for Uterine Cancer are looking for participants at sites in and around Baldwin Park (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
RecruitingPhase 4
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte · 4 mi away
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, Duarte · 4 mi away
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
RecruitingPhase 1
- City of Hope Medical Center, Duarte · 4 mi away
About Uterine Cancer
Uterine cancer is a cancer that forms in tissues of the uterus. It is more likely to happen after menopause. There are things you can do that may help lower your risk.
More about Uterine Cancer on MedlinePlus
Uterine Cancer trials in other cities
- Houston, TX8 studies
- New York City, NY6 studies
- Columbus, OH6 studies
- Boston, MA5 studies
- Philadelphia, PA5 studies
- Miami, FL5 studies
- Austin, TX5 studies
- West Palm Beach, FL4 studies
- Chicago, IL4 studies
- Providence, RI4 studies
- Orlando, FL4 studies
- Pittsburgh, PA4 studies
Other studies in Baldwin Park
- Breast Cancer44 studies
- Acute Myeloid Leukemia40 studies
- Colorectal Cancer37 studies
- Non-Small Cell Lung Cancer36 studies
- Cancer (all types)34 studies
- Prostate Cancer30 studies
- Metastatic Cancer30 studies
- Myelodysplastic Syndromes26 studies
- Ovarian Cancer25 studies
- Lung Cancer24 studies
- Multiple Myeloma23 studies
- Stomach Cancer22 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.